Annals of Clinical Neurophysiology

The Korean Society of Clinical Neurophysiology (대한임상신경생리학회)
권호 표지
DOI QR코드

DOI QR Code

Insight into the prognostic factors of chronic inflammatory demyelinating polyneuropathy

  • Baek, Seol-Hee (Department of Neurology, Korea University Anam Hospital, Korea University College of Medicine)
  • Received : 2019.11.18
  • Accepted : 2020.01.29
  • Published : 2020.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediated neuropathy with heterogeneous features. Appropriate treatment will produce a favorable outcome, but a poor treatment response and severe disability have also been reported. The roles of the clinical phenotypes and electrophysiological features of CIDP as well as of autoantibodies against nodal and paranodal proteins have been highlighted previously due to their association with the treatment response and long-term prognosis. This review addresses the diverse factors associated with the prognosis of CIDP.

Keywords

References

  1. McLeod J, Pollard J, Macaskill P, Mohamed A, Spring P, Khurana V. Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol 1999;46:910-913. https://doi.org/10.1002/1531-8249(199912)46:6<910::AID-ANA14>3.0.CO;2-2
  2. Lunn M, Manji H, Choudhary P, Hughes R, Thomas P. Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J Neurol Neurosurg Psychiatry 1999;66:677-680. https://doi.org/10.1136/jnnp.66.5.677
  3. Iijima M, Koike H, Hattori N, Tamakoshi A, Katsuno M, Tanaka F, et al. Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population. J Neurol Neurosurg Psychiatry 2008;79:1040-1043. https://doi.org/10.1136/jnnp.2007.128132
  4. Rajabally YA, Simpson BS, Beri S, Bankart J, Gosalakkal JA. Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a UK population. Muscle Nerve 2009;39:432-438. https://doi.org/10.1002/mus.21206
  5. Laughlin R, Dyck PJ, Melton L, Leibson C, Ransom J, Dyck PJB. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology 2009;73:39-45. https://doi.org/10.1212/WNL.0b013e3181aaea47
  6. Bouchard C, Lacroix C, Plante V, Adams D, Chedru F, Guglielmi JM, et al. Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology 1999;52:498-503. https://doi.org/10.1212/WNL.52.3.498
  7. Kuwabara S, Misawa S, Mori M, Tamura N, Kubota M, Hattori T. Long term prognosis of chronic inflammatory demyelinating polyneuropathy: a five year follow up of 38 cases. J Neurol Neurosurg Psychiatry 2006;77:66-70. https://doi.org/10.1136/jnnp.2005.065441
  8. Viala K, Maisonobe T, Stojkovic T, Koutlidis R, Ayrignac X, Musset L, et al. A current view of the diagnosis, clinical variants, response to treatment and prognosis of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 2010;15:50-56. https://doi.org/10.1111/j.1529-8027.2010.00251.x
  9. Rotta FT, Sussman AT, Bradley WG, Ayyar DR, Sharma KR, Shebert RT. The spectrum of chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 2000;173:129-139. https://doi.org/10.1016/S0022-510X(99)00317-2
  10. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-First Revision. J Peripher Nerv Syst 2010;15:1-9. https://doi.org/10.1111/j.1529-8027.2010.00245.x
  11. Kuwabara S, Isose S, Mori M, Mitsuma S, Sawai S, Beppu M, et al. Different electrophysiological profiles and treatment response in 'typical' and 'atypical' chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 2015;86:1054-1059. https://doi.org/10.1136/jnnp-2014-308452
  12. Fargeot G, Maisonobe T, Psimaras D, Debs R, Lenglet T, Adams D, et al. Comparison of Lewis-Sumner syndrome with chronic inflammatory demyelinating polyradiculoneuropathy patients in a tertiary care centre. Eur J Neurol 2020;27:522-528. https://doi.org/10.1111/ene.14101
  13. Doneddu PE, Cocito D, Manganelli F, Fazio R, Briani C, Filosto M, et al. Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP database. J Neurol Neurosurg Psychiatry 2019;90:125-132. https://doi.org/10.1136/jnnp-2018-318714
  14. Katz J, Saperstein D, Gronseth G, Amato A, Barohn R. Distal acquired demyelinating symmetric neuropathy. Neurology 2000;54:615-620. https://doi.org/10.1212/WNL.54.3.615
  15. Larue S, Bombelli F, Viala K, Neil J, Maisonobe T, Bouche P, et al. Non-anti-MAG DADS neuropathy as a variant of CIDP: clinical, electrophysiological, laboratory features and response to treatment in 10 cases. Eur J Neurol 2011;18:899-905. https://doi.org/10.1111/j.1468-1331.2010.03312.x
  16. Mygland A, Monstad P. Chronic acquired demyelinating symmetric polyneuropathy classified by pattern of weakness. Arch Neurol 2003;60:260-264. https://doi.org/10.1001/archneur.60.2.260
  17. Staudt M, Diederich J, Meisel C, Meisel A, Klehmet J. Differences in peripheral myelin antigen-specific T cell responses and T memory subsets in atypical versus typical CIDP. BMC Neurol 2017;17:81. https://doi.org/10.1186/s12883-017-0860-z
  18. Kuwabara S, Misawa S, Mori M. Chronic inflammatory demyelinating polyneuropathy: the spectrum and immunopathogenesis deciphered by electrophysiology and neuroimaging. Clin Exp Neuroimmunol 2018;9:47-53. https://doi.org/10.1111/cen3.12431
  19. Abraham A, Alabdali M, Qrimli M, Albulaihe H, Breiner A, Barnett C, et al. Treatment responsiveness in CIDP patients with diabetes is associated with higher degrees of demyelination. PLoS one 2015;10:e0139674. https://doi.org/10.1371/journal.pone.0139674
  20. Chin RL, Deng C, Bril V, Hartung HP, Merkies IS, Donofrio PD, et al. Follow-up nerve conduction studies in CIDP after treatment with IGIV-C: comparison of patients with and without subsequent relapse. Muscle Nerve 2015;52:498-502. https://doi.org/10.1002/mus.24624
  21. Iijima M, Yamamoto M, Hirayama M, Tanaka F, Katsuno M, Mori K, et al. Clinical and electrophysiologic correlates of IVIg responsiveness in CIDP. Neurology 2005;64:1471-1475. https://doi.org/10.1212/01.WNL.0000158680.89323.F8
  22. Baek SH, Hong YH, Choi SJ, Ahn SH, Park KH, Shin JY, et al. Electrodiagnostic data-driven clustering identifies a prognostically different subgroup of patients with chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 2019;90:674-680. https://doi.org/10.1136/jnnp-2018-319758
  23. Bril V, Banach M, Dalakas MC, Deng C, Donofrio P, Hanna K, et al. Electrophysiologic correlations with clinical outcomes in CIDP. Muscle Nerve 2010;42:492-497. https://doi.org/10.1002/mus.21733
  24. Rajabally Y, Narasimhan M. Distribution, clinical correlates and significance of axonal loss and demyelination in chronic inflammatory demyelinating polyneuropathy. Eur J Neurol 2011;18:293-299. https://doi.org/10.1111/j.1468-1331.2010.03138.x
  25. Koike H, Kadoya M, Kaida KI, Ikeda S, Kawagashira Y, Iijima M, et al. Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin-155 and anti-contactin-1 antibodies. J Neurol Neurosurg Psychiatry 2017;88:465-473. https://doi.org/10.1136/jnnp-2016-314895
  26. Devaux JJ, Miura Y, Fukami Y, Inoue T, Manso C, Belghazi M, et al. Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. Neurology 2016;86:800-807. https://doi.org/10.1212/WNL.0000000000002418
  27. Ng JKM, Malotka J, Kawakami N, Derfuss T, Khademi M, Olsson T, et al. Neurofascin as a target for autoantibodies in peripheral neuropathies. Neurology 2012;79:2241-2248. https://doi.org/10.1212/WNL.0b013e31827689ad
  28. Querol L, Nogales-Gadea G, Rojas-Garcia R, Martinez-Hernandez E, Diaz-Manera J, Suarez-Calvet X, et al. Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy. Ann Neurol 2013;73:370-380. https://doi.org/10.1002/ana.23794
  29. Garg N, Park SB, Yiannikas C, Vucic S, Howells J, Noto YI, et al. Neurofascin-155 IGG4 neuropathy: pathophysiological insights, spectrum of clinical severity and response to treatment. Muscle Nerve 2018;57:848-851. https://doi.org/10.1002/mus.26010
  30. Kadoya M, Kaida K, Koike H, Takazaki H, Ogata H, Moriguchi K, et al. IgG4 anti-neurofascin155 antibodies in chronic inflammatory demyelinating polyradiculoneuropathy: clinical significance and diagnostic utility of a conventional assay. J Neuroimmunol 2016;301:16-22. https://doi.org/10.1016/j.jneuroim.2016.10.013
  31. Ogata H, Yamasaki R, Hiwatashi A, Oka N, Kawamura N, Matsuse D, et al. Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy. Ann Clin Transl Neurol 2015;2:960-971. https://doi.org/10.1002/acn3.248
  32. Querol L, Siles AM, Alba-Rovira R, Jauregui A, Devaux J, Faivre-Sarrailh C, et al. Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy. Sci Rep 2017;7:14411. https://doi.org/10.1038/s41598-017-14853-4
  33. Miura Y, Devaux JJ, Fukami Y, Manso C, Belghazi M, Wong AHY, et al. Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia. Brain 2015;138(Pt 6):1484-1491. https://doi.org/10.1093/brain/awv054
  34. Mathey E, Garg N, Park S, Nguyen T, Baker S, Yuki N, et al. Autoantibody responses to nodal and paranodal antigens in chronic inflammatory neuropathies. J Neuroimmunol 2017;309:41-46. https://doi.org/10.1016/j.jneuroim.2017.05.002
  35. Doppler K, Appeltshauser L, Villmann C, Martin C, Peles E, Kramer HH, et al. Auto-antibodies to contactin-associated protein 1 (Caspr) in two patients with painful inflammatory neuropathy. Brain 2016;139(Pt 10):2617-2630. https://doi.org/10.1093/brain/aww189
  36. Querol L, Rojas-Garcia R, Diaz-Manera J, Barcena J, Pardo J, Ortega- Moreno A, et al. Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflamm 2015;2:e149. https://doi.org/10.1212/NXI.0000000000000149